Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in ≥3-Year-Olds
CTR20223413Phase 3Completed
- Sponsor
- Jiangsu Kangrun Biotechnology
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of influenza vaccine (split virion, inactivated, quadrivalent) in Influenza A infection and influenza B (2 arms), sponsored by Jiangsu Kangrun Biotechnology. Primary endpoints: HI antibody seroconversion rate (SCR) and geometric mean titer (GMT) for H1N1, H3N2, B (Victoria), B (Yamagata), HI antibody seroconversion rate (SCR) and seroprotection rate (SPR) for H1N1, H3N2, B (Victoria), B (Yamagata) and 1 more. Started Feb 2023; status: completed.
02
Drugs
influenza vaccine (split virion, inactivated, quadrivalent)
03
Conditions
Influenza A infectioninfluenza B
Beyond the preview
Go deeper on CTR20223413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223413.